[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.232.99. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1991

Topical Flurbiprofen Pretreatment Does Not Block Apraclonidine's Effect on Aqueous Flow in Humans

Author Affiliations

From the Mayo Medical School, Rochester, Minn (Mr McCannel); Department of Ophthalmology, Umea (Sweden) University Hospital (Dr Koskela); and the Department of Ophthalmology, Mayo Clinic and Mayo Foundation, Rochester (Dr Brubaker).

Arch Ophthalmol. 1991;109(6):810-811. doi:10.1001/archopht.1991.01080060074028
Abstract

• Flurbiprofen's effect on the ability of apraclonidine hydrochloride (para-aminoclonidine) to reduce aqueous humor flow was studied in 20 healthy human volunteers. Flurbiprofen sodium, in a 0.03% concentration, was administered topically to one eye and a placebo to the contralateral eye of each subject in a random, double-masked fashion. A total of four drops was administered to each eye during a 30-minute period beginning at 7 am. Thirty minutes later, one drop of 1% apraclonidine was instilled into each eye. Flow rates were measured with fluorophotometry from 7 am to noon. The mean (±SD) rate of flow after administration of flurbiprofen and apraclonidine at the peak of apraclonidine's effect was 1.56±0.50 μL/min, and after administration of placebo and apraclonidine was 1.53 0.43 μL/min. With a sample size of 20 and a coefficient of variation of flow measurement of 15%, there is a 95% chance of detecting a difference in flow rate of 15% or greater using the techniques employed in this study. Since there was no statistically significant difference between the rates of flow under the two conditions, we conclude that flurbiprofen has no appreciable effect on apraclonidine's ability to suppress aqueous flow.

×